研究表明,抗酸性药物tirzepatide可能会减慢小鼠乳腺癌的生长速度。 Study shows anti-obesity drug tirzepatide may slow breast cancer growth in mice.

在ENDO 2025年进行的一项研究表明,以用于糖尿病的Mounjaro和用于肥胖的Zepbound销售为Mounjaro的抗肥胖药物tirzepatide减少了小鼠与肥胖有关的乳腺癌的生长。 A study at ENDO 2025 showed that the anti-obesity drug tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity, reduced obesity-linked breast cancer growth in mice. 该药物将体重和脂肪减少约20%,与人类试验结果相似,并且与控制相比肿瘤体积减少。 The drug reduced body weight and fat by about 20%, similar to results in human trials, and decreased tumor size compared to controls. 研究人员认为,tirzepatide可能对乳腺癌的结果产生积极影响,但还需要开展更多的研究。 Researchers suggest that tirzepatide may have a positive impact on breast cancer outcomes, but more studies are needed.